Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alphalytik Pharmaservice GmbH | Contract Pharma

What are you searching for?

Sign in

Search by

Alphalytik Pharmaservice GmbH

Company Headquarters

44a Grünberger Straße, Berlin, BE, 10243, DE

Driving Directions Phone: View Phone
View website

Request more information from Alphalytik Pharmaservice GmbH

Request more information from Alphalytik Pharmaservice GmbH

Categories from Alphalytik Pharmaservice GmbH

Accelerated Stability Studies
Analytical Laboratory Services
Analytical Methods Development
Analytical Validation Studies
Chromatographic Analysis, LC/GC
Dissolution Testing
Forced Degradation Studies
HPLC
Photostability
Physical Testing
QA/QC
Stability Studies
Stability, ICH
Sterility Testing
Storage

Related Content

Breaking News

AustinPx KinetiSol Earns FDA AMT Designation

Solvent-free technology expands manufacturing options for poorly soluble oral drug candidates.

By: Charlie Sternberg

Collaborations & Alliances

ExploRNA, Łukasiewicz Research Network Partner on GMP Manufacturing of Next-Gen mRNA Cap Analogs

Łukasiewicz, known for advanced chemical synthesis and production scaling capabilities, will help ExploRNA ramp up its mRNA manufacturing.

By: Patrick Lavery

Breaking News

FDA Approves IntraBio’s Aqneursa as First Treatment for Ataxia-Telangiectasia

It is the second FDA-approved indication for Aqneursa, following Niemann-Pick disease type C.

By: Patrick Lavery

Breaking News

WuXi XDC Secures GMP Release for Singapore Manufacturing Site

The designation applies to the site’s BCM3 antibody intermediate and conjugated drug substance dual-function production line, and DP4 facility.

By: Patrick Lavery

Breaking News

Made Scientific Acquires Cell Therapy Facility From National Resilience

The 85,000-sq.-ft. East Norriton site adds GMP cleanrooms, fill-finish capacity, and immediate onboarding for cell therapy sponsors.

By: Charlie Sternberg

Collaborations & Alliances

mAbxience, Sandoz to Collaborate on Emicizumab Biosimilar Candidate

Treatment for hemophilia A remains a significant unmet medical need.

By: Patrick Lavery

Breaking News

Upperton Gains MHRA Approval for Nottingham Sterile Manufacturing Site

License variation supports early-phase GMP manufacture at Nottingham facility.

By: Charlie Sternberg

Online Exclusives

CDMO Capacity: Stainless by Volume, Single-Use by Number

Large stainless-steel projects are rising, but pipeline demand is increasingly moving toward smaller, more flexible manufacturing models.

By: Dan Stanton

Promotions & Moves

Prilenia Taps Rick Munschauer as New Chief Medical Officer

Munschauer has been CMO at three previous biopharmaceutical companies, most recently Emalex Biosciences.

By: Patrick Lavery

Northway Biotech Opens €61M Cell Therapy CDMO Facility in Vilnius

The 3,500-square-meter BIO CITY III facility adds up to 20 cGMP manufacturing lines for cell therapies and personalized medicine.

By: Tim Wright

Ebook

Advancing Small Molecules: Managing Complexity From Development Through Commercialization

Small molecules remain central to pharmaceutical innovation, but the development process is changing.

Released By Lonza

Breaking News

PerkinElmer Completes SimoTech Acquisition

Deal expands PerkinElmer’s automation, GMP IT and digital manufacturing capabilities for life sciences customers.

By: Charlie Sternberg

Breaking News

Q-VANT Santiago Facility Earns EXCiPACT GMP Certification

Certification supports commercial-scale production of QS-21 and other high-purity saponin fractions for human and veterinary vaccines.

By: Charlie Sternberg

Cell-Based Assays Under FDA Scrutiny: Lessons from Recent CRLs

Sponsored By Solvias

Trials & Filings

T-Maximum Gains FDA Fast Track Status for CAR-T Glioblastoma Therapy

MT027 previously received Orphan Drug Designation, and T-Maximum was authorized to start a Phase II study.

By: Patrick Lavery